MCM
NVCR icon

MAI Capital Management’s NovoCure NVCR Stock Holding History

MAI Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-75
Closed -$818 – 3819
2026
Q1 		$818 Buy
75
+17
+29% +$212 ﹤0.01% 4248
2025
Q4 		$750 Buy
58
+16
+38% +$205 ﹤0.01% 3722
2025
Q3 		$543 Sell
42
-130
-76% -$1.74K ﹤0.01% 3606
2025
Q2 		$3.06K Buy
172
+130
+310% +$2.27K ﹤0.01% 3274
2025
Q1 		$749 Hold
42
– – ﹤0.01% 3183
2024
Q4 		$1.25K Buy
+42
New +$889 ﹤0.01% 3140

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

MAI Capital Management's NVCR Position: Q2 2026 in Review

MAI Capital Management sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 75 shares — an estimated $818 sold.

MAI Capital Management first reported a position in NVCR in Q4 2024 and held it in 6 quarters. The position peaked at $3.06K in Q2 2025. 217 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • MAI Capital Management reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 75 NovoCure shares in Q2 2026, an estimated $818.
  • MAI Capital Management first reported a position in NovoCure in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's NovoCure position peaked at $3.06K in Q2 2025.
  • 217 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.